1. Introduction Cultivation of genetically modified crops in confined environ ments located in limited-access sites such as discontinued mines, caves, or warehouses(Philipkoski, 2004) can potentially enable production of plant-made pharmaceuticals(PMPs)and plant-made industrial compounds(PMICs), provided that adequate contain- ment precautions are rigorously followed. Maize(Zea mays L) grown in confined, controlled environments has been p as platform(Fischer Maize offers key advantages as reviewed by Lamphear et al. (2002) and Ramessar et al. (2008a,b). Advantages of producing PMPs/PMICs in maize seeds include stable protein storage, protein accumulation in a concentrated volume, durable seed coat that minimizes risk of pathogen infection during storage, yields typically higher than those of other cereals, existing transformation and seeds that contain few metabolites that might interfere with downstream purification processes for compounds of interest. Additionally,